Literature DB >> 23069645

Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.

Hitoshi Saito1, Satoshi Takeda, Norio Amizuka.   

Abstract

Vitamin D is known as a potent stimulator of bone resorption. The active form of vitamin D3, calcitriol (1α,25-dihydroxyvitamin D3), stimulates release of calcium (Ca) from bone in ex vivo organ culture, and treatment with large amounts of an active vitamin D3 analog induces hypercalcemia and bone resorption in mice in vivo. Calcitriol strongly induces both receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) in osteoblasts in vitro. On the other hand, it has been reported that active vitamin D3 inhibits bone resorption in various experimental animal models. We previously showed that eldecalcitol [1α,25-dihydroxy-2β-(3-hydroxy-propyloxy)vitamin D3; ED-71] suppresses bone resorption and increases bone mineral density (BMD) to a greater extent than alfacalcidol (1α-hydroxyvitamin D3) in ovariectomized (OVX) rats in vivo. To elucidate the histological events that follow administration of eldecalcitol compared to calcitriol, OVX rats were given either vehicle, eldecalcitol (10, 30, or 90ng/kg), or calcitriol (33.3, 100, 300, or 900ng/kg), and sham-operated control animals were given vehicle, 5-times per week for 12 weeks. The lumbar spine and femur were removed and processed for bone mineral density (BMD) assessments and the femur for histomorphometrical analyzes. Both eldecalcitol and calcitriol increased the lumbar and femoral BMD in a dose dependent manner. Bone histomorphometry revealed that osteoclast surface (Oc.S/BS) and eroded surface (ES/BS) were dose-dependently suppressed in the trabecular region of the femur. Both calcitriol and eldecalcitol dose-dependently stimulated focal bone formation that started without prior bone resorption, a process known as bone minimodeling. Both reduction of bone resorption and stimulation of focal bone formation were more clearly observed in the eldecalcitol-treated rats than in the calcitriol-treated rats. Taken together, these findings suggest that eldecalcitol is a more potent vitamin D3 analog that stimulates focal bone formation (minimodeling) and suppresses bone resorption more strongly than does calcitriol. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069645     DOI: 10.1016/j.jsbmb.2012.10.004

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  11 in total

1.  Histochemical examination of systemic administration of eldecalcitol combined with guided bone regeneration for bone defect restoration in rats.

Authors:  Xiuchun Han; Juan Du; Di Liu; Hongrui Liu; Norio Amizuka; Minqi Li
Journal:  J Mol Histol       Date:  2016-11-23       Impact factor: 2.611

2.  Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis.

Authors:  Kosuke Ebina; Masafumi Kashii; Makoto Hirao; Jun Hashimoto; Takaaki Noguchi; Kota Koizumi; Kazuma Kitaguchi; Hozo Matsuoka; Toru Iwahashi; Yasunori Tsukamoto; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2016-11-09       Impact factor: 2.626

Review 3.  Nanoparticulate drug delivery platforms for advancing bone infection therapies.

Authors:  Vuk Uskoković; Tejal A Desai
Journal:  Expert Opin Drug Deliv       Date:  2014-08-11       Impact factor: 6.648

4.  Effects of eldecalcitol on cortical bone response to mechanical loading in rats.

Authors:  Yusuke Yamasaki; Keita Nagira; Mari Osaki; Hideki Nagashima; Hiroshi Hagino
Journal:  BMC Musculoskelet Disord       Date:  2015-06-30       Impact factor: 2.362

5.  Beneficial effects of calcitriol on hypertension, glucose intolerance, impairment of endothelium-dependent vascular relaxation, and visceral adiposity in fructose-fed hypertensive rats.

Authors:  Chu-Lin Chou; Cheng-Yoong Pang; Tony J F Lee; Te-Chao Fang
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

6.  Eldecalcitol, an Active Vitamin D3 Derivative, Prevents Trabecular Bone Loss and Bone Fragility in Type I Diabetic Model Rats.

Authors:  Satoshi Takeda; Mitsuru Saito; Sadaoki Sakai; Kenji Yogo; Keishi Marumo; Koichi Endo
Journal:  Calcif Tissue Int       Date:  2017-06-17       Impact factor: 4.333

7.  Histomorphometric analysis of minimodeling in the vertebrae in postmenopausal patients treated with anti-osteoporotic agents.

Authors:  Tomohiro Hikata; Tomoka Hasegawa; Keisuke Horiuchi; Nobuyuki Fujita; Akio Iwanami; Kota Watanabe; Ken Ishii; Masaya Nakamura; Norio Amizuka; Morio Matsumoto
Journal:  Bone Rep       Date:  2016-10-13

Review 8.  Eldecalcitol for the treatment of osteoporosis.

Authors:  Yuko Noguchi; Hisaya Kawate; Masatoshi Nomura; Ryoichi Takayanagi
Journal:  Clin Interv Aging       Date:  2013-09-27       Impact factor: 4.458

9.  Evidence for Ongoing Modeling-Based Bone Formation in Human Femoral Head Trabeculae via Forming Minimodeling Structures: A Study in Patients with Fractures and Arthritis.

Authors:  Hiroshige Sano; Naoki Kondo; Taketoshi Shimakura; Junichi Fujisawa; Yasufumi Kijima; Tomotake Kanai; Kenneth E S Poole; Noriaki Yamamoto; Hideaki E Takahashi; Naoto Endo
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-19       Impact factor: 5.555

10.  Eldecalcitol is more effective in promoting osteogenesis than alfacalcidol in Cyp27b1-knockout mice.

Authors:  Yoshihisa Hirota; Kimie Nakagawa; Keigo Isomoto; Toshiyuki Sakaki; Noboru Kubodera; Maya Kamao; Naomi Osakabe; Yoshitomo Suhara; Toshio Okano
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.